Fri, Aug 29, 2014, 9:04 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Compugen Ltd. (CGEN) Message Board

suejenseth 26 posts  |  Last Activity: Aug 21, 2014 9:33 AM Member since: Sep 26, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • suejenseth by suejenseth Aug 21, 2014 9:33 AM Flag

    I view this mornings announcement as a positive. The deal had been modified several times over the years and I never fully understood the accounting. I did understand the need on our side. Baize invested this money when the stock price was considerably lower and we would have had to have gone to the outside for it at greater dilution. I imagine these shares were already accounted for in any diluted share count. Now we will have to see what our discoveries are worth.


  • Reply to

    Seeking Alpha

    by suejenseth Aug 14, 2014 4:39 PM
    suejenseth suejenseth Aug 14, 2014 7:45 PM Flag

    SBH, based on your comments on another thread I was thinking of posting something earlier so I will I was catching up on some reading and looked at the September 28th Barrons that had an interview with the head of the vanguard healthcare fund (The case for Merck, Medtronic, and more). She had a few comments about Merck and Bristol Myers and their immunotherapy drugs being their leading candidates for growth, also mentions Roche and Astra in this space. Not a lot there but as I said emphasis on growth, I am talking about multiple tens of billions of valuation. We are so under the radar I find it incredible. Maybe we will always be there, never having the break through we hope for. But I don't think that will be the case. One day it will happen.
    By the way the weather today in New York is spectacular, hope Boston sharing same.


  • suejenseth by suejenseth Aug 14, 2014 4:39 PM Flag

    Hard to believe based on volume but there was a seeking alpha article about us today. The article does not provide any new insight for those of us who follow but the title is good.

    Biotech Millions To Be Made In CGEN And AGEN


  • Reply to

    CGEN contact question

    by bauersteven12 Aug 8, 2014 4:12 PM
    suejenseth suejenseth Aug 11, 2014 2:37 PM Flag

    Steven, I am not sure an individual investor will get through on a quarterly call. At one time you could but now that a few firms follow on the call I don't think they are so apt to accept.
    My contact over the years was Dikla, what I did was send a message to set up a time with her for a phone call. We have a new CFO so that might not get you what you want. I went to Israel to meet with Martin and Dikla, I set it up months in advance. I also very briefly met Anat, just a hello. At that time I was told she was very busy and did not have the time. A few months later the Bayer deal.
    As SBH, alluded don't set your heights to high on expectations there are limits to what they will say especially in writing.
    Regarding whether science is proven I think you have to look at it two ways. I think we have proven that we have been able to discover very "promising" potential drugs. I would imagine the new checkpoints are real. What we have not established is do they matter. Can we turn these phenomena into drugs. As we go through preclinical to clinical we will learn. But your concern is legitimate we do not know that yet.
    SBH, you are right about 2-4 years in preclinic. But let me state the obvious for many of us including you. We have been around here a lot longer then 2-4 years waiting for something to happen. Much has but not confirmed commercially yet.

  • Reply to

    todays call

    by suejenseth Aug 6, 2014 3:16 PM
    suejenseth suejenseth Aug 6, 2014 5:15 PM Flag

    Elbit, the transcript is out but you have to go to the seeking alpha website to get it. It is no longer shown on Yahoo. It is not easy to read. Too technical for me, but you can get a strong sense of accomplishment.
    Aziz your comments are right on. Anat and the team appear to be to be unique and brilliant. Our time will come.

  • suejenseth by suejenseth Aug 6, 2014 3:16 PM Flag

    Since no one has written I figured I would take a crack.
    What is impressive is the scientific progress, as we are now making strides on many fronts. It was nice to have Dr. Hunter on the call. I am not sure if we got any new information though. It seems like the next call may be much more interesting as the company appears to remain committed to its objectives.
    For the cynics among us, sometimes including myself, it continues to be...wait till next year.
    I did not see the transcript published yet, I hope it comes since it can be difficult to understand the scientific terminology and the accent.
    I use the ignore button a lot, I cant believe how many ignores I have. DLP, loved your recent missive. If I come here and am not logged onto my yahoo account I will see all the messages even those in response to ignore. I try to stay logged on.


  • suejenseth by suejenseth Aug 5, 2014 10:36 AM Flag

    Slow until tomorrow. I believe we will get a review of objectives for the year. Anyway just for something to write there was an article written titled Triple therapy revs up immune system against common brain tumor

    it was about some of the work being done by members of our scientific committee. Always glad to know we are working with folks in the forefront of technology. The members were Pardoll and Drake. Pardoll's bio does not mention his association with us, but then again article does not spell Bristol-Myers correctly either. Drakes does. I would imagine we are destined to a deal with Bristol-Myers but that is just me. Also, appreciate their contacts and that they started and sold Amplimmune.

    Charles Drake has served as a consultant for Amplimmune, Bristol-Meyers Squibb, Compugen, Dendreon, ImmunExcite and Roche/Genentech and is on the Scientific Advisory Board of Compugen. He receives research funding from Bristol-Meyers Squibb, Aduro and Janssen and has stock ownership in Compugen. Drew Pardoll is a consultant/advisor for Jounce Therapeutics, Bristol-Meyers Squibb, ImmuneXcite and Aduro and receives research funding from Bristol-Meyers Squibb. Jing Zeng, Michael Lim, Charles Drake and Drew Pardoll hold a patent for the work related to this study


  • Reply to

    Valuation ramblings

    by bauersteven12 Jul 25, 2014 4:02 PM
    suejenseth suejenseth Jul 29, 2014 3:48 AM Flag

    Irony good post. Regarding your last comment about large biotechs getting into our space, though I am not a fan of us selling out, wouldn't it be MUCH cheaper for a large company to purchase us then to try and recreate our efforts. Even if they had to pay a hefty premium?


  • suejenseth by suejenseth Jul 26, 2014 9:18 PM Flag

    Bauersteven12, I did not like the answer that I gave. I wanted to take another crack at it.
    A couple of things. I believe Compugen ended 2103 at 8.95. Since then, it has had 15% dilution, an embarrassing CFO incident, a biotech crash, a war in Its home country, no new deals and it is selling at 8.5. All things considered the stock has held in. Why is that?
    Because it is in a hot field, with recognized science. We know that by its scientific committee and by the presentations they are giving. During this period they have expanded their portfolio and if cgen is to meet its current objectives will be expanding its portfolio again in one of the most exciting areas in pharmaceuticals this year. Deals will come and they will come more quickly in the future.
    Regarding Isis it gets a lot of play and it may be well deserved I do not know the company but looking at a two year chart you will see the stock was as low as 9. It has had a very up and down past. Over the next two years I don't see why we can not get a big run up in our stock.
    I have to much of this stock and that has been the case for a number of years now. When MG or Anat begin to sell their stock. I will begin to sell mine. That has not happened yet.

  • Reply to

    Valuation ramblings

    by bauersteven12 Jul 25, 2014 4:02 PM
    suejenseth suejenseth Jul 25, 2014 4:52 PM Flag

    bauersteven, I appreciate you writing this. I go through the same concerns almost every day. My hope is that we will have the valuation of isis or sgen or even incy in the not distant future. Regarding stock price of isis it ran into the same issues as cgen, sgen and many others. A bubbled biotech market that crashed. I am sure there might be one or two other factors but ultimately that's what happened.
    I purchased this stock for several personal reasons years ago. MG had a track record and the idea of using algorithms to find drugs was pretty interesting. But from my perspective up until three years ago we were floundering. We had good science but had no idea what to do with it. We thought large pharmaceutical companies would just hire us to find drug candidates. The mission was wrong there was no interest and we were going nowhere.
    MG finally saw the light or at least Anat told him where it was shining three years ago and finally cgen realized it had to conduct itself like every other biotech and bring their candidates along. As I think of it we were like a start up. We had a great(we hope) platform but no drugs and not a lot of money. So we began to build. MG did the Baize deal which gave us the funds to start the California operation. Anat made what appears to be a great decision by looking at immunotherapy drugs. But we were still going so slow. It feels like one program a year. Now we did a money raise. Some may not like that we did it at 10.50 but if we did it 18 months ago it would have been for less then $5 with much greater dilution. Now we are running a number of programs. I expect that over the next eighteen months will have some pretty significant deals as our programs mature. I suspect we will have some of our own in clinicals. I suspect assuming a normal market our valuation will rise quite a bit. If my expectations are wrong and we are still waiting for some indication for this to happen in the next six months, I will be paring back, foolish not to

  • Reply to


    by azizabortnick Jul 24, 2014 8:48 AM
    suejenseth suejenseth Jul 24, 2014 11:41 AM Flag

    Can not argue with your statement. If I am not mistaken on the last call, it was mentioned that another researcher in addition to Dr. Miller was being brought in. So to your point a lot of research behind something that could be a pretty big deal. When we finally license this out I hope we get one heck of a deal.
    Though not stock movers these types of announcements at least indicate respect in the field.

  • Reply to

    Lilly, Immunocore to develop cancer immunotherapies

    by sbh3117 Jul 17, 2014 12:23 PM
    suejenseth suejenseth Jul 18, 2014 3:00 PM Flag

    By the way SBH, have a little nugget for you. Both Cgen and Immunocore are attending ImVacs, The Immunotherapeutics and Vaccine Summit" in August. Difference is they are attending and we are presenting. We must be doing something right...........We'll see.


  • Reply to

    Lilly, Immunocore to develop cancer immunotherapies

    by sbh3117 Jul 17, 2014 12:23 PM
    suejenseth suejenseth Jul 17, 2014 9:28 PM Flag

    Thanks SBH, everyday is a nice day :) so yes I am having a nice summer. Absolutely understand why you posted and like Bauer I immediately went to company website.
    I believe you are correct that immunotherapy is hot and will hopefully cure a lot of people in the future. I have been betting that we, cgen, will be curing many folks in the future.
    But you know it is what is so darn frustrating for many of us. Large pharma knows who we are, you would think they would be dying to partner with us and maybe they are but it just goes so slow. It has been a year since Bayer I don't think any of us thought it was going to take a year to get another partnership. There is a lot I could say here but it is just repeating what I and some others have said.....basically where is the beef.
    Guys like Aziz and I have to be able to accept when market risk causes our stock to fall, it just tends to highlight the riskiness of this type of investment. Anyway if we cant get a deal done in this very hot area this year then you have to question what is going on and think about paring back.
    However in the immortal words of Tug McGraw "You gotta believe" it will be OK. I believe w will be responsible for saving many lives and that is a good thing.

    Peace please peace

  • Reply to

    Lilly, Immunocore to develop cancer immunotherapies

    by sbh3117 Jul 17, 2014 12:23 PM
    suejenseth suejenseth Jul 17, 2014 3:56 PM Flag

    SBH, how should we feel about this. Nice deal for Immunocare, which has several deals with large pharma companies, immunocare also has a phase 1/2 clinical going. It is private so have no idea of its value to Street.

    We have to contend with ill timed comments by the fed chief (more on that this weekend) and a mid east war. All the "heroic" investors panic and leave.

    A deal like immunocares would be very helpful I think, better yet several deals would be helpful. For whatever reason these things come very slowly to us or after discovering our checkpoints three or four years ago they remain in such early stages that we cant get what we think they are worth (a nice way of saying no one wants them)
    Then again who knows what Monday will bring. My guess all will be well and those of us who stick around will be happy with what we get. As investors here we deserve every penny.

    I hope for peace,

  • Reply to

    Pipeline expands again

    by gs88gs88 Jul 14, 2014 7:33 AM
    suejenseth suejenseth Jul 15, 2014 10:50 AM Flag

    Though we have had three rather interesting announcements in the last month our stock price does not seem to recognize the potential increase in value. One of the issues we have to contend with is Ms Yellens concern that Biotech companies have stretched valuations. Those of us who believe that this is not the case for cgen can not fight a biotech sell off. Eventually we should win out with continued progress.

  • Reply to

    todays announcement

    by suejenseth Jul 7, 2014 12:35 PM
    suejenseth suejenseth Jul 7, 2014 5:31 PM Flag

    Thanks guys for the birthday wishes. DLP, It was a tough day for many small biotechs and though it would have been much better to see a more positive reaction on a relative basis we did better.
    SBH and Cam you are correct a milestone payment is positive, that is the bottom line. Since we do not know the schedule of payments it is very difficult to tell what progress is being made or how Bayer is approaching its testing. Maybe our next call will give a clue or perhaps another payment is in the cards this year.
    Anyway it is time to get a beer, the best to all.

  • suejenseth by suejenseth Jul 7, 2014 12:35 PM Flag

    Well the half full story is that Bayer is moving the programs along and has not returned them to us. Don't underestimate that. This is just part of the process.
    Unfortunately seems like half empties are winning today. Let me be a half empty for a moment. You mean after Bayer has been working with our stuff for a year we get a milestone on one protein for $1.2 mil. Even if this works how far are we from getting to clinical trials. Is this it? Is this the update we have been waiting for? As a long term holder everything seems to take forever. Is it another lost year? When is another pharma going to partner with us already?
    I am not going anywhere but I am celebrating another birthday today. Time is fleeting.


  • suejenseth by suejenseth Jun 30, 2014 12:30 PM Flag

    Not a big fan of their research but they did rank us a number one.

    Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
    • Arbor Realty Trust Inc (ABR)
    • Banco Bradesco SA (BBD)
    • Capital Bank Financial Corp (CBF)
    • Cash America International Inc (CSH)
    • Compugen Ltd. (CGEN)


  • suejenseth by suejenseth Jun 26, 2014 5:09 PM Flag

    Bummer day but 2 weeks ago I was sure we would be around $7.50. We were selling at 8 with a triple witch and a quarter ends. Smelled like trouble. Today seems like some portfolio adjusting but I admit I have no idea.

    I do know this if you go to the company’s website you will notice two new events posted one in August where we will be speaking. It looks like the agenda was set before we announced 15052. We will be talking about 15049. I always like to review sponsors and other speakers. Take a look.

    There is a poster presented by Dr. Joe Podojil of North Western on our fc fusion candidate 15001 in June. I like to see this since our concentration is on immune oncology but we have more. Regarding 15001 I put in a quote from the last conference call transcript.
    Anat “In support of these efforts, we recently expanded our long-standing collaboration with Professor Steve Miller from Northwestern University to further study immune tolerance being used by CGEN-15001 and to start translational research using biological sensors from open immune patients. We are also about to enter a new collaboration with an addition leading expert in the field, expanding the translational research activities involving CGEN-15001.
    I would like to see an announcement if possible on this new collaboration. Some of us, (me, Aziz) were very disappointed that we did not move this along to clinical trials. But if we preclinical the heck out of it will no doubt increase its value.
    Anyway there are better days ahead. Second half of year only days away and that is when things will happen.

  • suejenseth suejenseth Jun 24, 2014 7:42 PM Flag

    SBH, I just think this is interesting though it does not have a direct effect on us. Bristol-Myers announced some phase 3 results on their PD-! drug that appear to be quite good. I note it since this is a checkpoint drug. My bet we are pretty close to an announcement but that is just pure speculation on my part. I know patience, patience.


8.90+0.06(+0.68%)Aug 29 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.